Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX EBITDA Margin

EBITDA as a percentage of revenue.

Apyx Medical CorporationNASDAQ: APYX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -3.4%

EBITDA Margin was -3.4% in Q1 FY2026, up 24.2 pp from a year earlier. On a trailing-twelve-month basis it was -4.4%, up 24.0 pp year over year. Over 3 fiscal years it widened by 40.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -5.2% for the fiscal year ending Dec 2026, up from -8.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-3.4%-5.9 pp QoQ
Last fiscal yearDec 2025
-8.7%+26.2 pp YoY
LTMMar 2026
-4.4%+24.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+24.2 pp+3.3 pp-20.9 pp
1 year+26.2 pp+3.5 pp-22.8 pp
3 years+40.8 pp+11.3 pp-29.5 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-8.7%
Year-over-year change
+26.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 EBITDA Margin of -4.4% is the 3rd highest of the 7 companies compared; the peer median is -91.7%.
  • Its year-over-year change of +24.0 pp is the 2nd highest of 7, against a peer median of +10.6 pp.
  • Over three fiscal years its change of +40.8 pp compares with a peer median of +20.8 pp.
APYX Competitors Peer median
EBITDA Margin for APYX and competitors
Company Period LTM level YoY 3-year change
PDEXPro-Dex, Inc.LTM Mar 202626.3% +4.7 pp+4.8 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 20269.7% +12.3 pp+21.2 pp
APYXApyx Medical CorporationLTM Mar 2026-4.4% +24.0 pp+40.8 pp
RCELAVITA Medical, Inc.LTM Mar 2026-52.1% +18.1 pp+20.4 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-131.2% +8.9 pp+214.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-859.3% +600.4 pp+13170.1 pp
SERASera Prognostics, Inc.LTM Mar 2026-54764.9% -26826.7 pp-22063.2 pp
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding APYX) -91.7%+10.6 pp+20.8 pp

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.52M44.51M52.35M48.1M52.84M
Cost of Revenue14.92M15.38M18.59M18.74M33.81M
Gross Profit33.6M29.13M33.76M29.36M19.03M
Gross Margin69.3%65.4%64.5%61.0%36.0%
Research & Development4.32M4.54M4.84M5.08M3.37M
Selling, General & Admin43.73M48.15M48.87M43.13M36.12M
Operating Expenses48.05M52.69M51.02M48.21M25.48M
Depreciation & Amortization903K890K692K599K655K
EBITDA(13.91M)(22.01M)(18.11M)(16.8M)(4.59M)
EBITDA Margin-28.7%-49.4%-34.6%-34.9%-8.7%
Operating Income(14.45M)(23.56M)(17.26M)(18.85M)(6.45M)
Operating Margin-29.8%-52.9%-33.0%-39.2%-12.2%
Interest Income11K157K921K1.61M1.11M
Interest Expense10K15K2.48M5.91M5.59M
Other Income / Expenses(372K)651K(4.02M)(4.46M)(4.39M)
Income Before Tax(14.82M)(22.91M)(21.28M)(23.31M)(10.84M)
Pre-Tax Margin-30.5%-51.5%-40.7%-48.5%-20.5%
Income Tax Expense380K367K(2.43M)252K270K
Net Income(15.17M)(23.18M)(18.71M)(23.46M)(11.21M)
Net Margin-31.3%-52.1%-35.7%-48.8%-21.2%
EPS (Basic)(0.44)(0.67)(0.54)(0.66)(0.27)
EPS (Diluted)(0.44)(0.67)(0.54)(0.66)(0.27)
Weighted Avg Shares34.33M34.52M34.62M35.54M42.16M
Weighted Avg Shares (Diluted)34.33M34.52M34.62M35.54M42.16M

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.